Last reviewed · How we verify
Desloratadine (Clarinex)
Desloratadine is a selective histamine H1-receptor antagonist that blocks histamine-mediated allergic responses without significant central nervous system penetration.
Desloratadine is a selective histamine H1-receptor antagonist that blocks histamine-mediated allergic responses without significant central nervous system penetration. Used for Allergic rhinitis (seasonal and perennial), Chronic idiopathic urticaria.
At a glance
| Generic name | Desloratadine (Clarinex) |
|---|---|
| Also known as | SCH 034117, Clarinex |
| Sponsor | Organon and Co |
| Drug class | Non-sedating H1-receptor antagonist |
| Target | Histamine H1 receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology / Allergy |
| Phase | Phase 3 |
Mechanism of action
Desloratadine competitively binds to peripheral H1 receptors on mast cells and basophils, preventing histamine release and its downstream effects on smooth muscle contraction, vasodilation, and itching. As a non-sedating antihistamine, it has minimal blood-brain barrier penetration due to its molecular structure and substrate for efflux transporters, making it suitable for daytime use in allergic conditions.
Approved indications
- Allergic rhinitis (seasonal and perennial)
- Chronic idiopathic urticaria
Common side effects
- Headache
- Somnolence
- Fatigue
- Dry mouth
- Pharyngitis
Key clinical trials
- Autologous Whole Blood Therapy in Chronic Idiopathic Urticaria Patients. (PHASE3)
- Desloratadine to Prevent Taxane-induced Peripheral Neuropathy in Patients With Breast Cancer (PHASE2)
- Desloratadine in Patients With Ulcerative Colitis (PHASE2)
- A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis (PHASE3)
- Contribution of Nasal IgE Production to the Boost of Systemic Allergen-specific IgE Upon Nasal Allergen Contact (NA)
- Fixed Dose Combination of Desloratadine / Prednisolone in the Treatment of Moderate Severe Allergic Rhinitis in Children (PHASE3)
- Confirmatory Study on the Efficacy and Safety of the Fixed-dose Combination of Desloratadine/Betamethasone Versus Desloratadine (PHASE3)
- The Effect of Omalizumab on Allergic Rhinitis Symptoms: a Comparative Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Desloratadine (Clarinex) CI brief — competitive landscape report
- Desloratadine (Clarinex) updates RSS · CI watch RSS
- Organon and Co portfolio CI